Skip to main content
Premium Trial:

Request an Annual Quote

UgenTec Taps Thermo Fisher to Commercialize CE-Marked FastFinder Plug-ins for PCR Assays

NEW YORK – Belgian molecular laboratory software vendor UgenTec said Thursday that it has entered into a deal with Thermo Fisher Scientific to jointly commercialize several new CE-marked respiratory assay plug-ins for its FastFinder analysis software. The collaboration will allow FastFinder to analyze and interpret results from Thermo Fisher's TaqPath COVID-19 CE-IVD RT-PCR kit and the TaqPath COVID-19, Flu A/B, and RSV Combo kit from a single software platform.

The deal expands on a relationship UgenTec has had with Thermo Fisher, including support for SARS-CoV-2 PCR testing from Thermo Fisher and various other vendors at 35 private and public laboratories in France.

"With this next step, we can provide our joint customer labs with a compliant sample-to-result solution that builds on our [artificial intelligence] and data science capabilities to help them scale with a compliant solution," UgenTec CEO Steven Verhoeven said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.